6BG logo

Lytix Biopharma DB:6BG Stock Report

Last Price

€0.45

Market Cap

€23.9m

7D

-22.4%

1Y

7.9%

Updated

23 Dec, 2024

Data

Company Financials +

My Notes

Capture your thoughts, links and company narrative

Lytix Biopharma AS Competitors

Price History & Performance

Summary of share price highs, lows and changes for Lytix Biopharma
Historical stock prices
Current Share PriceNOK 0.45
52 Week HighNOK 1.04
52 Week LowNOK 0.41
Beta-0.67
1 Month Change-17.03%
3 Month Change-28.32%
1 Year Change7.86%
3 Year Change-67.60%
5 Year Changen/a
Change since IPO-71.26%

Recent News & Updates

Recent updates

Shareholder Returns

6BGDE BiotechsDE Market
7D-22.4%-3.5%-2.0%
1Y7.9%-14.7%6.9%

Return vs Industry: 6BG exceeded the German Biotechs industry which returned -14.7% over the past year.

Return vs Market: 6BG matched the German Market which returned 6.9% over the past year.

Price Volatility

Is 6BG's price volatile compared to industry and market?
6BG volatility
6BG Average Weekly Movement12.4%
Biotechs Industry Average Movement6.8%
Market Average Movement4.9%
10% most volatile stocks in DE Market11.3%
10% least volatile stocks in DE Market2.4%

Stable Share Price: 6BG's share price has been volatile over the past 3 months compared to the German market.

Volatility Over Time: 6BG's weekly volatility (12%) has been stable over the past year, but is still higher than 75% of German stocks.

About the Company

FoundedEmployeesCEOWebsite
2003n/aOystein Rekdalwww.lytixbiopharma.com

Lytix Biopharma ASA, a clinical stage biotech company, develops novel cancer immunotherapies for cancer therapy in Norway. Its lead product candidate is LTX-315, an oncolytic molecule that is developed for intratumoral injections, is designed for the local treatment of solid tumors that is in Phase II clinical trials. The company’s products comprise of LTX-401, an oncolytic molecule for targeting deep-seated lesions, such as liver cancer and is in a preclinical phase.

Lytix Biopharma AS Fundamentals Summary

How do Lytix Biopharma's earnings and revenue compare to its market cap?
6BG fundamental statistics
Market cap€23.92m
Earnings (TTM)-€6.85m
Revenue (TTM)€910.03k

26.3x

P/S Ratio

-3.5x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
6BG income statement (TTM)
RevenueNOK 10.76m
Cost of RevenueNOK 0
Gross ProfitNOK 10.76m
Other ExpensesNOK 91.68m
Earnings-NOK 80.92m

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)-1.63
Gross Margin100.00%
Net Profit Margin-752.26%
Debt/Equity Ratio0%

How did 6BG perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/23 05:44
End of Day Share Price 2024/12/20 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Lytix Biopharma AS is covered by 1 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Carl RamaniusRedeye